Edasalonexent

N/A

Report date: 2025/10/02 20:00:08
NME

Base Information

Drug NameEdasalonexent
Drug Alias Name依达奈珍Docosahexaenoic acid-sodium salicylate conjugate艾得奈生Sodium salicylate-docosahexaenoic acid conjugateedasalonexentum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsDiabetes Mellitus, Type 2Muscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstria Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstria Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Muscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A